KPV vs LL-37
Alpha-MSH Fragment · Cathelicidin
Here is how these two compounds compare, based on published research, not marketing claims.
KPV
Suppresses inflammation through NF-kB inhibition and has antimicrobial properties; the active fragment of alpha-MSH.
LL-37
Directly kills bacteria and fungi by disrupting their membranes; the only cathelicidin antimicrobial peptide in the human immune system.
KPV
27 studies
0 human trials
Not FDA-Approved
LL-37
3096 studies
7 human trials
Not FDA-Approved
What it does
KPV
Reduces inflammation and inhibits microbial growth in the gut and on the skin. The active fragment of alpha-MSH, a hormone the body naturally produces to regulate inflammation and immune responses.
LL-37
Directly kills bacteria, fungi, and some viruses by disrupting their cell membranes, while simultaneously modulating the broader immune response to coordinate defense and wound healing. The only cathelicidin antimicrobial peptide produced by the human body.
How it works
KPV
KPV is a three-amino-acid peptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds the melanocortin-1 receptor (MC1R) and suppresses NF-kB, a master switch that controls inflammatory gene expression. By turning down NF-kB signaling, KPV reduces production of inflammatory cytokines like IL-1 beta and TNF-alpha. Separately from its anti-inflammatory pathway, KPV has demonstrated direct antimicrobial and antifungal activity in laboratory studies, suggesting a dual-action mechanism.
LL-37
LL-37 is a 37-amino-acid peptide cleaved from its precursor protein hCAP-18. It functions through a dual mechanism: direct antimicrobial action and immunomodulation. The antimicrobial action works by inserting into and disrupting microbial cell membranes, physically destroying bacteria and fungi. The immunomodulatory function works by recruiting immune cells to infection sites, modulating inflammatory cytokine production, and supporting wound healing. LL-37 is produced by neutrophils, epithelial cells, and other immune cells as part of the innate immune defense. Its expression is partially regulated by vitamin D, which is why vitamin D deficiency is associated with increased susceptibility to certain infections.
How often
KPV
In published research, KPV has been studied in oral, topical, and injectable formulations across animal models of colitis and skin inflammation. No FDA-approved product exists. No standardized clinical dosing protocol has been established through regulatory channels.
LL-37
In published research, LL-37 has been studied in topical, injectable, and inhaled formulations across various infection and wound healing models. No FDA-approved LL-37 therapeutic product exists. The compound is available through research peptide markets. No standardized clinical dosing protocol has been established.
How strong
KPV
The anti-inflammatory mechanism through NF-kB suppression is well-characterized at the cellular level. Animal models of inflammatory bowel disease show reduced colitis severity. Topical skin inflammation models show measurable improvement. Human clinical data is absent.
LL-37
Well-characterized as a fundamental component of human innate immunity. Published antimicrobial efficacy data across multiple pathogen types. The dual antimicrobial plus immunomodulatory mechanism is extensively documented. Human expression studies and vitamin D regulation pathway are well-established. Some clinical development programs (wound healing, infection) have been initiated but none have achieved FDA approval.
Main tradeoff
KPV
Strong mechanistic rationale with zero published human clinical trials. The animal data on gut inflammation and skin healing is consistent across multiple models, but the translation to human therapeutic use is entirely unvalidated. The compound's small size (3 amino acids) raises questions about bioavailability and stability that have not been answered in human pharmacokinetic studies.
LL-37
Extensively studied as an endogenous defense molecule but limited clinical development as a therapeutic. The antimicrobial mechanism (membrane disruption) is broad-spectrum but also raises concerns about host cell toxicity at higher concentrations. Stability and delivery challenges have limited clinical translation. The compound is well-understood biologically but not yet clinically validated as an exogenous therapeutic.
Best for
KPV
- Research on alpha-MSH-mediated anti-inflammatory signaling through the MC1R pathway
- Research on NF-kB suppression as a therapeutic target in inflammatory bowel disease models
- Research on peptide-based antimicrobial mechanisms distinct from traditional antibiotics
LL-37
- Research on innate immune defense mechanisms and cathelicidin antimicrobial peptides
- Research on dual-function peptides that combine direct pathogen killing with immunomodulation
- Research comparing membrane-disrupting antimicrobials (LL-37) with NF-kB-suppressing anti-inflammatories (KPV)
How to choose
A good fit for KPV
- Research on NF-kB suppression as an anti-inflammatory strategy in gut or skin models
- Research on alpha-MSH-mediated inflammatory modulation
- Research contexts where the primary question is inflammation control rather than pathogen killing
A good fit for LL-37
- Research on direct antimicrobial peptide mechanisms and membrane disruption
- Research on innate immune defense coordination and wound healing
- Research on the intersection of antimicrobial defense and vitamin D biology
Consider both across time
KPV and LL-37 approach the inflammation-infection axis from opposite directions. KPV addresses the inflammatory cascade (turning down NF-kB signaling that drives tissue damage). LL-37 addresses the pathogens that trigger inflammation (killing bacteria and fungi directly). For gut inflammation research where both bacterial presence and inflammatory damage matter, both mechanisms are relevant. KPV has animal colitis data; LL-37 has extensive basic immunology characterization. Neither has been validated as a clinical therapeutic.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- MC1R Receptor
- MC1R Receptor activates NF-κB Suppression
- NF-κB Suppression suppresses Inflammatory Cytokine Reduction
- MC1R Receptor enables Direct Antimicrobial Activity
- Inflammatory Cytokine Reduction connects to Inflammation Reduction
- Direct Antimicrobial Activity connects to Microbial Clearance
- Microbial Membrane Disruption
- Immune Cell Recruitment
- Immune Cell Recruitment modulates Inflammatory Modulation
- Immune Cell Recruitment supports Wound Healing Support
- Microbial Membrane Disruption kills Direct Pathogen Killing
- Inflammatory Modulation connects to Immune Response Modulation; Wound Healing Support connects to Immune Response Modulation
KPV binds the MC1R receptor and suppresses NF-kB inflammatory signaling, reducing production of inflammatory cytokines.
LL-37 inserts into and disrupts microbial cell membranes while recruiting immune cells to infection sites.
Research Evidence
LL-37 has dramatically more published research as a biological molecule: thousands of papers characterizing its role in innate immunity. KPV has a smaller but focused body of work on NF-kB suppression in inflammatory models. As therapeutic candidates, both are early-stage: KPV has zero human clinical trials; LL-37 has limited therapeutic development despite being well-characterized biologically.
- 1.
For inflammation reduction without immunosuppression, KPV has the more targeted mechanism.
- 2.
For antimicrobial applications or biofilm-related conditions, LL-37 is the relevant compound.
- 3.
For gut inflammation specifically, KPV has some preclinical data but no human validation.
- 4.
For evidence depth, LL-37 has vastly more published research, though most is preclinical.
Key Limitations
- •Both are early-stage with minimal human data.
- •KPV has no human studies at all.
- •LL-37's research is extensive but primarily in vitro.
- •Direct comparison is premature given both compounds' early development status.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
KPV
"KPV healed my leaky gut"
Insufficient evidence
"KPV works orally, you don't need to inject it"
Plausible mechanism
LL-37
"LL-37 cured my chronic infection"
Insufficient evidence
"LL-37 is the body's natural antibiotic"
Supported by evidence
Safety Comparison
Both are derived from endogenous molecules. KPV is the C-terminal fragment of alpha-MSH, a hormone the body produces naturally. LL-37 is produced by immune cells as part of innate defense. Neither has formal human safety data from therapeutic trials. LL-37's membrane-disrupting mechanism raises theoretical host-cell toxicity concerns at high concentrations. KPV's small size (3 amino acids) raises bioavailability questions.
KPV
Very limited data. As a short endogenous peptide fragment, theoretical safety is favorable.
LL-37
Endogenous, your body makes it. Limited therapeutic dose safety data.
What the Research Suggests
Both are interesting early-stage immune peptides targeting different problems. LL-37 has more research behind it. KPV has a more novel anti-inflammatory mechanism. Neither is ready for confident clinical recommendations.